Welcome to our dedicated page for Unity Biotechnology news (Ticker: UBX), a resource for investors and traders seeking the latest updates and insights on Unity Biotechnology stock.
Unity Biotechnology, Inc. (NASDAQ: UBX) is a leading biotechnology company focused on developing innovative therapeutics aimed at extending human healthspan by targeting age-related diseases. The company's pioneering approach centers on creating senolytic medicines, which selectively eliminate senescent cells – cells that contribute to aging and various diseases. Unity's initial efforts are directed toward treating conditions such as osteoporosis, eye diseases, and pulmonary diseases.
Unity’s main drug candidates include:
- UBX1325: A promising treatment for age-related eye diseases, including diabetic macular edema (DME). UBX1325 recently demonstrated positive results in the Phase 2 ENVISION study, maintaining vision gains and significantly reducing anti-VEGF treatment needs in patients with wet AMD.
- UBX2089: A circulating hormone being studied for multiple neurological conditions.
- UBX2050: Another investigational drug aimed at age-associated diseases.
Recently, Unity announced the successful results from Part B of the Phase 2 ENVISION study for UBX1325, highlighting its safety and efficacy in maintaining visual acuity and reducing the treatment burden for patients with wet AMD who were not receiving optimal benefits from ongoing anti-VEGF therapy. The study showed that 40% of UBX1325-treated patients did not require anti-VEGF rescue through 48 weeks.
Unity's current focus is on its DME program, where UBX1325 showed a statistically significant improvement in visual acuity during the Phase 2 BEHOLD study. The company has initiated a Phase 2b study and plans to randomize the first patient in Q4 2023. Additional data from the ENVISION study is expected to be presented at upcoming medical conferences.
About the ENVISION Study: The Phase 2 ENVISION study is a multi-center, randomized, double-masked, active-controlled study evaluating the safety, tolerability, efficacy, and durability of UBX1325 in combination with aflibercept for patients with neovascular AMD.
For more detailed information, visit www.unitybiotechnology.com.
UNITY Biotechnology announced results from the Phase 2 ENVISION study of UBX1325 for wet age-related macular degeneration (AMD) on March 27, 2023. UBX1325 maintained visual acuity in patients over 24 weeks, with less than one letter mean decrease from baseline. However, it did not achieve non-inferiority compared to anti-VEGF control, which saw an unexpected gain of 3.5 letters. Notably, 52% of UBX1325 patients did not need anti-VEGF treatments during the study. The company plans to release 48-week data from the BEHOLD DME study in April and initiate a Phase 2b study in DME in the latter half of 2023.
UNITY Biotechnology, Inc. (UBX) reported its financial results for Q4 and FY 2022, with a cash position of $94.8 million, sufficient to fund operations into Q1 2024. Achievements included positive 24-week data from the Phase 2 BEHOLD study for UBX1325 and completion of enrollment in the Phase 2 ENVISION study for age-related macular degeneration. The operating loss for 2022 was $57.6 million, slightly up from $56.7 million in 2021. R&D expenses decreased by $1.5 million YoY, reflecting cost reductions, despite an increase in direct expenses for UBX1325. The upcoming milestone includes 24-week data from ENVISION expected by the end of March 2023.
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 – UNITY Biotechnology, a biotechnology firm focused on therapeutics to address aging-related diseases, announced its participation in the Cowen 43rd Annual Health Care Conference. The event is scheduled for March 7, 2023, at 9:50 AM ET, featuring updates from the Company’s Management and one-on-one investor meetings. The presentation will be accessible via webcast and also through the ‘Investors and Media’ section on their website. UNITY's mission includes developing treatments to eliminate or modulate senescent cells, specifically targeting age-related ophthalmologic and neurologic diseases.
UNITY Biotechnology [NASDAQ: UBX] has scheduled a corporate update and one-on-one investor meetings at the SVB Securities Global Biopharma Conference on February 15, 2023, at 11:20 AM ET. The company focuses on developing therapeutics to address diseases of aging, particularly targeting age-related ophthalmologic and neurologic diseases by eliminating or modulating senescent cells. The presentation will be accessible via webcast and can also be found on their website under the 'Investors and Media' section.
UNITY Biotechnology, Inc. (NASDAQ: UBX) announced an investor call scheduled for February 14, 2023, at 7:00 a.m. PT, featuring retinal expert Dr. Robert B. Bhisitkul. The call will discuss data from the Phase 2 BEHOLD study on UBX1325 for diabetic macular edema and updates on the ENVISION study focused on wet age-related macular degeneration (AMD). Notably, complete 16- and 24-week safety and efficacy data from the ENVISION study are expected in Q1 2023. A live Q&A will follow the presentation. Interested investors can access the webcast on the company’s website or view it later in the 'Events & Presentations' section.
UNITY Biotechnology, Inc. (NASDAQ: UBX), a biotechnology firm focused on therapeutics that address aging-related diseases, disclosed that from January 3 to January 17, 2023, its Board's Compensation Committee granted a stock-based award of 900 shares to a new employee. This grant was made under the amended 2020 Employment Inducement Incentive Plan, aimed at attracting new talent in compliance with Nasdaq Rule 5635(c)(4). UNITY is currently working on therapies to target and eliminate senescent cells, with a focus on age-related ophthalmologic and neurologic diseases.
UNITY Biotechnology reported positive results from the Phase 2 BEHOLD study of UBX1325 for treating Diabetic Macular Edema, showing a 7.6-letter improvement in BCVA after 24 weeks. The drug demonstrated a favorable safety profile. UNITY's financial position improved, with cash and equivalents totalling $103.9 million as of September 30, 2022. This funding is expected to support operations into Q1 2024. A reduction in operating loss to $13.1 million, down from $14.8 million, reflects enhanced efficiency in operations.
UNITY Biotechnology announced positive results from the Phase 2 BEHOLD study of UBX1325 in diabetic macular edema (DME), showing a significant improvement in Best Corrected Visual Acuity (BCVA) of +7.6 letters compared to sham treatment after 24 weeks (p=0.0084). UBX1325 also stabilized retinal structure as measured by central subfield thickness. Notably, 59.4% of treated patients did not require anti-VEGF rescue therapy after 6 months. Following these promising outcomes, the company plans to initiate a pivotal study in DME in the second half of 2023.
UNITY Biotechnology (Nasdaq:UBX) is set to host a program update on its lead therapeutic UBX1325 for age-related diseases on November 1, 2022. The session features retinal expert Dr. Arshad M. Khanani, highlighting advancements in treatments aimed at senescent cells to combat aging-related conditions. This update signifies a pivotal moment in the company’s ongoing efforts to revolutionize therapies for ophthalmologic and neurological diseases.
UNITY Biotechnology (Nasdaq: UBX) has announced a 1-for-10 reverse stock split effective October 19, 2022, at 5:00 PM ET, with trading on a split-adjusted basis starting October 20, 2022. This action aims to ensure compliance with Nasdaq's minimum bid price requirement. The reverse split was approved by stockholders on October 18, 2022, and will convert every 10 shares into one. Stockholders entitled to fractional shares will receive cash payment. For further details, refer to the SEC filings and the company's website.
FAQ
What is the current stock price of Unity Biotechnology (UBX)?
What is the market cap of Unity Biotechnology (UBX)?
What is Unity Biotechnology's primary focus?
What diseases is Unity Biotechnology targeting?
What is UBX1325?
What were the latest results from the ENVISION study?
What are the current projects of Unity Biotechnology?
Where can I find more information about Unity Biotechnology?
What is the significance of senolytic medicines?
Has UBX1325 been approved for use?
What is the expected timeline for the ASPIRE study?
What partnerships does Unity Biotechnology have?
